VTP 45489
Alternative Names: VTP-45489Latest Information Update: 15 Sep 2023
At a glance
- Originator Vitae Pharmaceuticals
- Developer Allergan
- Class Small molecules
- Mechanism of Action Retinoic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 03 Aug 2016 Preclinical trials in Autoimmune disorders in USA (unspecified route) before August 2016